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Prevalence of polypharmacy in the older adult 
population within primary care in Portugal:  
a nationwide cross-sectional study
Pedro Augusto Simões1, Luiz Miguel Santiago2, José Augusto Simões3
A b s t r a c t
Introduction: Polypharmacy is commonly defined as the simultaneous use 
of five or more medications; however, there is a lack of consensus regarding 
the most appropriate definition. It is a  significant predictor of morbidity 
and mortality. The aim of this study was to determine the prevalence of 
polypharmacy in the population of older adults attending primary care in 
Portugal and to identify associated sociodemographic and clinical factors.
Material and methods: We conducted a  cross-sectional, analytical study 
in primary care centres from the five Portuguese healthcare administrative 
regions and the two autonomous regions. We used a  random sample of 
757 older adult patients provided by the information department of the 
ministry of health (SPMS) and family doctors from the autonomous regions. 
Data collection occurred in March 2018. The variables utilised were sociode-
mographic characteristics, clinical profile and medication. For each patient, 
polypharmacy was measured either by the concurrent use of ≥ 5 drugs or by 
the median number of drugs at the time of data collection. Logistic regres-
sion analyses were performed to determine associations between polyphar-
macy and other variables.
Results: Polypharmacy (≥ 5 drugs) was present in 77% of the sample. A cut-
off of over the median number of drugs was present in 55%. The likeli-
hood of having polypharmacy increased significantly with age (OR = 1.05 
(1.02–1.08)), number of chronic health problems (OR = 1.24 (1.07–1.45)) 
and number of prescribers (OR = 4.71 (3.42–6.48)). Cardiovascular, meta-
bolic and musculoskeletal medications were the most commonly involved 
in polypharmacy.
Conclusions: Polypharmacy was a very common occurrence in Portugal. Fu-
ture primary healthcare policies should address polypharmacy.
Key words: polypharmacy, aged, multimorbidity.
Introduction
Polypharmacy is commonly defined as the simultaneous use of five 
or more drugs [1]. But other definitions has been proposed: some au-
thors propose a more detailed breakdown of the cut-off (“5 to 7” and 
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“8 and over”), allowing for the identification of 
those with an increased risk [2]; Steinman et al. 
[3] proposes a threshold of 8 medications justified 
by the fact that below this number, the risk of un-
der-use is greater than the risk of polypharmacy 
or inappropriate prescription; and others consider 
polypharmacy as the use of inappropriate, ineffec-
tive or duplicate medication [4].
Polypharmacy is estimated to affect 30–70% of 
older adults [5], and it has been associated with 
an increased risk of falls [6], inappropriate pre-
scriptions, reduced patient adherence, drug inter-
actions, hospital admissions [7] and mortality [8]. 
It is estimated that at least 75% of these adverse 
events are potentially preventable [9]. In some cas-
es, an adverse drug reaction can be misinterpreted 
as a new medical condition and a new drug is pre-
scribed, placing the patient at a higher risk of devel-
oping additional adverse drug reactions; this prob-
lem is known as the “prescribing cascade” [10].
According to Charlesworth et al. [11] the in-
creased number of prescription medications seen 
in older adults in the USA between 1988 and 2010 
was driven, in part, by higher use of cardioprotec-
tive medications (statins, anti-hypertensives, and 
antidiabetics). Still the use of antidepressants, as 
well as the use of medication from other classes 
and subclasses (proton-pump inhibitors, thyroid 
hormones, bisphosphonate, among others), also 
increased.
In Portugal there are a  few studies about the 
prevalence of polypharmacy in some of its regions, 
none on a national scale. A 2016 study in a pri-
mary care health centre in the north of Portugal 
identified a prevalence of polypharmacy of 59.2%, 
higher in women (62%) than in men (54.8%) [12]. 
In the Portuguese public health system the pa-
tients can only go to secondary care through re-
ferral from primary care, but once in both levels of 
care both doctors can prescribe and renew all the 
patient’s medications. The medications’ prescrip-
tion occurs through the mandatory nationwide 
electronic prescription platform (PEM).
The aim of this study was to identify the na-
tionwide prevalence of polypharmacy in older 
adults in Portugal and its sociodemographic and 
clinical profiles. Although polypharmacy can be 
linked to drug-drug interactions (both pharmaco-
kinetics and pharmacodynamics) and to adverse 
drug reactions, these results were presented in 
a previous paper [13]. Moreover, given the lack of 
consensus for the definition of polypharmacy and 
since multimorbidity and the use of multiple med-
ications is common in older adults [14] we also 
intended to use a new definition of polypharmacy 
(equal to or greater than the median number of 
drugs taken by the population) and compare it to 
the most commonly used.
Material and methods
Study design
A  cross-sectional study whose details, defini-
tions and methods were previously published [15]. 
The study was conducted in agreement with 
the principles of the Declaration of Helsinki and 
received ethical approval from the Institutional 
Ethics Committee of the University of Beira In-
terior and Portuguese Healthcare Administrative 
Regions. The reporting of this study conforms to 
the Strengthening the Reporting of Observational 
Studies in Epidemiology (STROBE) statement.
Participants
Since there were 2.18 million older adults 
(≥ 65 years) in Portugal and the literature suggests 
that the range of polypharmacy is between 30% 
and 70%, we assumed the rate to be over 50% 
because of epidemiological concern for better ev-
idence and larger sampling. We estimated a sam-
ple of a minimum 742 patients for a 95% CI and 
a maximum precision error of 5%. In agreement 
with the geographical distribution of the pop-
ulation of Portuguese aged 65 and older across 
the five mainland healthcare administrative re-
gions and two autonomous regions (Madeira and 
Azores), noted in PORDATA [16], a  random sam-
ple of 757 patients was provided by the informa-
tion department of the ministry of health, SPMS 
(Serviços Partilhados do Ministério da Saúde), and 
invited family doctors from autonomous regions, 
due to lack of digital databases within these re-
gions.
Data collection procedures
Data collection occurred in March 2018 (data 
extracted on March 30th). In brief, the SPMS pro-
vided us with an electronic file with the variables 
of the study from the randomly selected (by pa-
tient’s national health number) sample of the five 
healthcare administrative regions. This electron-
ic file contained anonymised information stored 
in the patient’s electronic medical records. Since 
SPMS does not have access to electronic medical 
records from patients in the two autonomous re-
gions, we invited two medical doctors, one from 
each autonomous region, to provide us with the 
needed information. The patients selected met 
the inclusion criteria and also had had an appoint-
ment in six pre-randomized days of the month. 
We studied the prescribed medications using the 
mandatory nationwide PEM [17]. There is an un-
known number of over-the-counter medications 
consumed by the Portuguese population and as 
they can be bought without prescription, there is 
no way to access this information. SPMS could not 
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provide us with information regarding level of ed-
ucation, since in most cases it was missing from 
the medical records.
Outcome variable
For each patient, polypharmacy was measured 
either by the simultaneous taking of ≥ 5 drugs 
or by the median number of drugs at the time of 
data collection. The rationale for such a study re-
sides in the lack of consensus regarding definition 
of polypharmacy [18]; also because of multimor-
bidity older patients are consuming an increasing 
number of medications [19]. There is a study [2] 
that proposes a  threshold of 8 medications, jus-
tified by the fact that below this number, there 
is a big risk of under-use. Prescribed medication 
(from April 2017 to March 2018) was encoded 
following the Portuguese pharmacotherapeutic 
classification using the most discriminative level 
possible. The Portuguese pharmacotherapeutic 
classification has similarities with the ATC (Ana-
tomical Therapeutic Chemical) classification and 
was adapted by INFARMED (National Authority of 
Medicines and Health Problems) [20]. We defined 
chronic medication as medication prescribed for 
more than three months.
Independent variables
These were sociodemographic characteristics 
such as age, gender (male/female), area of resi-
dence (in terms of health administrative region) 
and clinical profile (chronic health problems ac-
cording to International Classification of Primary 
Care, second edition – ICPC-2).
Compliance with ethical standards
Ethical approval was obtained from Institution-
al Ethics Committee at the University of Beira In-
terior and Portuguese Healthcare Administrative 
Regions.
Statistical analysis
In addition to the descriptive analysis, we also 
performed the χ2 test for nominal qualitative char-
acteristics. Lastly, we performed a logistic regres-
sion with all the statistically significant variables. 
All tests were two-sided using a significance level 




The sample consisted of 757 people, mean age 
was 75.5 ±7.9 years (75.1 ±7.9 years for men and 
75.8 ±7.8 years for women) and median number 
of drugs was 8. Table I shows the characteristics 
of the sample.
Prevalence of polypharmacy
More than 9 out of 10 older patients (93.4%) 
were on at least 1 medication, with an overall av-
erage of 8.2 (95% CI: 7.9–8.6), 7.5 (95% CI: 7–8) in 
men and 8.8 (95% CI: 8.3–9.3) in women. 
The rate of polypharmacy, use of 5 or more 
drugs simultaneously, was 77% (95% CI: 74–80%). 
With a cut-off of equal to or more than the medi-
an number of drugs (equal to 8), an important per-
centage of polypharmacy 55% (95% CI: 51–58%) 
remained present.
According to Table II there was a  significant 
relationship between health administrative re-
gion, age, number of chronic health problems and 
number of prescribers and both definitions for 
polypharmacy (≥ 5 drugs and ≥ median number 
of drugs). Gender was only significant in our new 
definition of polypharmacy.
After adjustments, Table III shows that the 
likelihood of having polypharmacy (as ≥ 5 drugs) 
increased significantly with age (OR = 1.05 (1.02–
1.08)), number of chronic health problems (OR = 
1.24 (1.07–1.45)) and number of prescribers (OR = 
4.71 (3.42–6.48)). 
The likelihood of having polypharmacy with our 
new definition (as ≥ median of drugs taken by the 
sample) increased significantly in females (OR = 
1.86 (1.24–2.80)), with number of chronic health 
problems (OR = 1.11 (1.02–1.20)) and number of 
prescribers (OR = 2.32 (1.97–2.73)).
Pharmacological subclasses and patterns  
of polypharmacy
Table III shows the odds ratio measured im-
pact of having each specific chronic health prob-
lem (according to ICPC2). For patients suffering 
from chronic health problems related to the car-
diovascular system there were 3.8 times and 2.4 
times greater probability of having polypharmacy 
(as ≥ 5 drugs and ≥ median number of drugs tak-
en, respectively) compared to those not suffer-
ing from health problems related to that specific 
system.
Table IV shows the most used pharmacological 
subclasses in this random sample. Three pharma-
cological subclasses were present in more than half 
of the sample: ACE inhibitor/ARBs (56.8%), statins 
(52%) and analgesics and antipyretics (50.6%).
Comparation between both definitions 
of polypharmacy in detecting potentially 
inappropriate medication
The common definition (≥ 5 drugs taken) had 
a sensitivity of 91.3%, specificity of 54.2%, posi-
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tive predictive value of 81.3% and negative pre-
dictive value of 74.1%.
Our definition (≥ median number of drugs tak-
en) had a sensitivity of 72.6%, specificity of 84.0%, 
positive predictive value of 90.8% and negative 
predictive value of 58.5%.
The mean number of PIM in older adults with 
polypharmacy according to the common definition 
was 2.19 (95% CI: 2.03–2.34) compared to 0.34 
(95% CI: 0.24–0.44) in those without polypharma-
cy. According to our definition (≥ median number 
of drugs taken) we found a  prevalence of 2.64 
PIMs (95% CI: 2.46–2.83) in those with polyphar-
macy compared to 0.69 PIMs (95% CI: 0.58–0.80).
Discussion
As described in the project protocol [15], the 
objectives for its phase I were to identify the prev-














< 75 51.5 (390)
≥ 75 48.2 (365)






≥ 11 17.2 (130)


































≤ 2 63.9 (484)
> 2 36.1 (273)
A  – general and unspecified, B – blood, blood forming organs, lymphatics, spleen, D – digestive, F – eye, H – ear, K – circulatory, 
L – musculoskeletal, N – neurological, P – psychological, R – respiratory, S – skin, T – endocrine, metabolic and nutritional, U – urology, 
X – female genital system and breast, Y – male genital system, Z – social problems, 2 – central nervous system, 3 – cardiovascular system, 
4 – blood, 5 – respiratory system, 6 – digestive system, 7 – genitourinary system, 8 – hormones and medications used to treat endocrine 
diseases, 9 – locomotive system, 10 – antiallergic medication, 16 – antineoplastic and immunomodulatory drugs.
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Table II. Prevalence of polypharmacy according to characteristics




Percentage of older adults with polypharmacy 
(95% CI)
Mean number of drugs 
(95% CI) [median]
≥ 5 drugs P-value
(χ2 test)
≥ 8 drugs P-value
(χ2 test)
Gender: 0.059 < 0.001
Women 20.5 (88) 79.5 (342) 60.5 (260) 8.78 (8.30–9.25) [8]




North 26.6 (65) 73.4 (179) 49.6 (121) 7.77 (7.18–8.36) [7]
Centre 17.9 (34) 82.1 (156) 58.9 (112) 8.62 (7.96–9.28) [8]
Lisbon-Tejo Valley 20.0 (42) 80.0 (168) 59.5 (125) 8.69 (8.02–9.36) [8]
Alentejo 27.3 (18) 72.7 (48) 53.0 (35) 7.48 (6.33–8.64) [8]
Algarve 41.2 (14) 58.8 (20) 41.2 (14) 6.29 (4.49–8.10) [6]
Madeira 14.3 (1) 85.7 (6) 28.6 (2) 9.43 (5.13–13.73) [6]
Azores 0 (0) 100 (6) 100 (6) 14.17 (9.50–18.83) [13]
Age [years]: < 0.001 0.001
< 75 28.2 (110) 71.8 (280) 49.2 (192) 7.73 (7.25–8.22) [7]
≥ 75 17.4 (64) 82.6 (303) 60.8 (223) 8.72 (8.24–9.21) [9]
Number of chronic 
health problems
< 0.001 < 0.001
0-2 48.1 (63) 51.9 (68) 35.9 (47) 5.44 (4.67–6.21) [5]
3-4 35.6 (52) 64.4 (94) 41.1 (60) 6.97 (6.17–7.78) [6]
5-6 23.3 (31) 76.7 (102) 48.1 (64) 7.80 (7.06–8.55) [7]
7-8 12.6 (16) 87.4 (111) 63.8 (81) 9.22 (8.50–9.94) [9]
9-10 7.8 (7) 92.2 (83) 64.4 (58) 9.21 (8.36–10.06) [9]
≥ 11 3.8 (5) 96.2 (125) 80.8 (105) 11.15 (10.34–11.95) [10]
Chronic health 
problems (ICPC2):
A 10.6 (9) 89.4 (76) 0.004 62.4 (53) 0.139 9.40 (8.42–10.38) [9]
B 15.8 (9) 84.2 (48) 0.179 66.7 (38) 0.062 9.25 (7.98–10.52) [9]
D 13.0 (36) 87.0 (240) < 0.001 60.1 (166) 0.026 8.93 (8.38–9.49) [8,5]
F 17.4 (27) 82.6 (128) 0.065 63.9 (99) 0.011 9.25 (8.43–10.08) [9]
H 12.6 (11) 87.4 (76) 0.015 63.2 (55) 0.094 9.70 (8.58–10.82) [9]
K 16.9 (99) 83.1 (488) < 0.001 61.2 (359) < 0.001 8.98 (8.60–9.37) [9]
L 17.6 (69) 82.4 (323) < 0.001 62.0 (243) < 0.001 8.95 (8.49–9.42) [8]
N 16.0 (19) 84.0 (100) 0.047 67.2 (80) 0.003 10.06 (9.13–10.99) [10]
P 16.5 (43) 83.5 (217) 0.002 60.4 (157) 0.026 9.01 (8.43–9.59) [8]
R 10.7 (19) 89.3 (158) < 0.001 67.2 (119) < 0.001 9.72 (9.03–10.41) [9]
S 19.2 (28) 80.8 (118) 0.224 56.2 (82) 0.717 8.66 (7.87–9.44) [8]
T 17.3 (90) 82.7 (429) < 0.001 60.5 (314) < 0.001 8.97 (8.56–9.38) [9]
U 16.0 (26) 84.0 (137) 0.016 65.0 (106) 0.003 9.09 (8.35–9.83) [9]
X* 10.9 (7) 89.1 (57) 0.041 67.2 (43) 0.233 9.72 (8.45–10.99) [10]
Y** 19.1 (22) 80.9 (93) 0.030 58.3 (67) 0.004 8.63 (7.78–9.47) [8]
Z 18.5 (5) 81.5 (22) 0.574 63.0 (17) 0.387 9.44 (7.65–11.24) [10]
Pharmacological 
classes (INFARMED):
2 9.2 (52) 90.8 (512) < 0.001 68.8 (388) < 0.001 9.77 (9.42–10.12) [9]
3 11.8 (73) 88.2 (546) < 0.001 63.8 (395) < 0.001 9.35 (9.01–9.69) [9]
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alence and its characteristics of polypharmacy 
and PIMs in the elderly Portuguese population. 
The results related to the PIMs have already been 
published [13], but they are not necessarily relat-
ed to the polypharmacy.
Strengths of the study
This was the first study to report the prevalence 
and patterns of polypharmacy in older adults at-
tending primary care consultations on a national 
scale in Portugal. 
We performed a  cross-sectional study, which 
is the most frequent design to assess prevalence 
and its characteristics. 
We used the most discriminative chemical sub-
group of the Portuguese pharmacotherapeutic 
classification, to assess polypharmacy; this can 
minimize the bias of medical changes. 
We assessed the number of medications taken 
by older adults using doctor’s prescription records 
to minimise memory bias. 
Since the data were mainly obtained by SPMS 
from national records (which allowed for a more 
representative sample of the population) and 
by sampling according to the patient’s national 
health number in most health regions, we avoided 
over-representation of frequent users of primary 
care services (normally the ones with a  higher 
number of morbidities and medication). 
Statement of overall findings
The study results show a  high prevalence of 
polypharmacy in the Portuguese older population 
(77%), exceeding the reported prevalence of oth-
er studies (30–70%) [5]. One of the explanations 
can be the period of time we used in this study 
(12-months), which can increase polypharmacy 
[21], making this high prevalence misrepresenta-
tive of reality, since medication could have been 
ceased. We used a more prolonged period of time 
because we believed it would allow differentiation 
between chronic and acute medication, done by 
evaluating the number of times each medication 
was prescribed in order to obtain a  more accu-
rate value [22]. Further research is needed to bet-
ter assess which methodology is more suitable, 
a 12-month or a 6-month period. 
Another possible explanation is that we as-
sessed the prescribed drugs and not the ones that 
were dispensed or consumed by the patient (ther-
apeutic adhesion). This may be misrepresentative 
of reality; patients could have stopped taking their 
medication (due to adverse effects, financial prob-
lems, etc.) and not have informed their doctor. 
On the other hand, we did not consider over-the-
counter medications and the medications pre-
scribed without the use of the electronic program 
PEM (e.g. manually), which may have a  residual 
effect. 
It is likely that differences in the rate of poly-
pharmacy can be found at the prescriber level 
[14]. This variation could be explained by practi-
tioners single-handedly treating diseases and ill-
nesses and the lack of guidelines regarding poly-
pharmacy or its prescription [23]. However, efforts 
to address polypharmacy within evidence-based 
deprescribing guidelines are being pursued [24].




Percentage of older adults with polypharmacy 
(95% CI)
Mean number of drugs 
(95% CI) [median]
≥ 5 drugs P-value
(χ2 test)
≥ 8 drugs P-value
(χ2 test)
4 2.5 (7) 97.5 (272) < 0.001 83.5 (233) < 0.001 11.27 (10.78–11.75) [11]
5 7.5 (12) 92.5 (148) < 0.001 78.1 (125) < 0.001 11.14 (10.42–11.85) [11]
6 5.7 (22) 94.3 (361) < 0.001 78.1 (299) < 0.001 10.81 (10.37–11.24) [10]
7 13.6 (17) 86.4 (108) 0.006 63.2 (79) 0.039 9.49 (8.68–10.30) [9]
8 8.4 (27) 91.6 (295) < 0.001 74.2 (239) < 0.001 10.64 (10.14–11.14) [10]
9 8.6 (35) 91.4 (373) < 0.001 74.3 (303) < 0.001 10.11 (9.69–10.53) [10]
10 5.2 (8) 94.8 (146) < 0.001 79.9 (123) < 0.001 11.07 (10.39–11.76) [11]
16 0 (0) 100 (12) 0.056 91.7 (11) 0.010 13.58 (9.80–17.37) [13.5]
Number of prescribers: < 0.001 < 0.001
≤ 2 34.5 (167) 65.5 (317) 39.5 (191) 6.48 (6.10–6.86) [6]
> 2 2.6 (7) 97.4 (266) 82.1 (224) 11.29 (10.78–11.80) [11]
*Considering only women, **considering only men. A  – general and unspecified, B – blood, blood forming organs, lymphatics, spleen, 
D – digestive, F – eye, H – ear, K – circulatory, L – musculoskeletal, N – neurological, P – psychological, R – respiratory, S – skin, 
T – endocrine, metabolic and nutritional, U – urology, X – female genital system and breast, Y – male genital system, Z – social problems, 
2 – central nervous system, 3 – cardiovascular system, 4 – blood, 5 – respiratory system, 6 – digestive system, 7 – genitourinary system, 
8 – hormones and medications used to treat endocrine diseases, 9 – locomotive system, 10 – antiallergic medication, 16 – antineoplastic 
and immunomodulatory drugs.
Table II. Cont.
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Table III. Logistic regression model for polypharmacy 
Characteristics Polypharmacy
≥ 5 drugs ≥ 8 drugs
OR 95% CI P-value OR 95% CI P-value
Gender:
Women – – – 1.86 1.24–2.80 0.003
Men – – – Base – –
Age 1.05 1.02–1.08 0.002 1.02 1.00–1.04 0.109
Number of chronic 
health problems:
1.24 1.07–1.45 0.005 1.11 1.02–1.20 0.016
A 1.17 0.47–3.00 0.735 – – –
D 1.55 0.88–2.75 0.131 0.77 0.51–1.16 0.204
F – – – 0.91 0.56–1.47 0.696
H 1.20 0.49–2.91 0.688 – – –
K 2.43 1.37–4.30 0.002 2.53 1.56–4.11 < 0.001
L 0.66 0.39–1.13 0.130 0.99 0.67–1.48 0.974
N 0.62 0.31–1.27 0.195 1.13 0.68–1.87 0.644
P 0.98 0.55–1.75 0.953 0.96 0.64–1.46 0.851
R 1.19 0.61–2.33 0.619 1.06 0.68–1.67 0.788
T 1.49 0.86–2.61 0.159 1.32 0.87–2.01 0.192
U 0.67 0.35–1.26 0.214 1.03 0.64–1.65 0.909
X 1.24 0.45–3.38 0.678 – – –
Y 0-77 0.39–1.53 0.451 1.33 0.75–2.33 0.329
Number of 
prescribers
4.71 3.42–6.48 < 0.001 2.32 1.97–2.73 < 0.001
OR – odds ratio, A  – general and unspecified, D – digestive, F – eye, H – ear, K – circulatory, L – musculoskeletal, N – neurological, 
P – psychological, R – respiratory, S – skin, T – endocrine, metabolic and nutritional, U – urology, X – female genital system and breast, 
Y – male genital system.
Table IV. Fifteen most used pharmacological subclasses and common chronic health problems
INFARMED pharmacotherapeutic  
classification
% (n) ICPC-2 chronic health problems % (n)
3.4.2      ACE inhibitor/ARBs 56.8 (430) K86     Hypertension uncomplicated 54.7 (414)
3.7.1      Statins 52.0 (394) T93     Lipid disorder 48.1 (364)
2.10       Analgesics and antipyretics 50.6 (383) T90     Diabetes non-insulin dependent 24.0 (182)
6.2.2.3   PPIs 38.2 (289) L86     Back syndrome with radiating pain 17.7 (134)
3.4.1.1   Thiazide 37.5 (284) L90     Osteoarthrosis of knee 16.2 (123)
2.9.1.3   Benzodiazepines 33.6 (254) T82     Obesity 14.8 (112)
3.4.3      Calcium channel blockers 26.7 (202) K87     Hypertension complicated 14.1 (107)
2.9.3      Antidepressants 24.7 (187) P76     Depressive disorder 13.2 (100)
4.3.1.3   Antiplatelet agents 23.6 (179) Y85     Benign prostatic hypertrophy 12.9 (98)
9.1.3       NSAIDs – propionic acid 
derivatives
22.3 (169) T83     Overweight 12.2 (92)
3.4.4.2   β-Blockers 21.9 (166) L91     Osteoarthrosis other 10.8 (82)
8.4.2.1   Biguanide 21.4 (162) K95     Varicose veins of leg 10.0 (76)
8.2         Corticosteroids 18.1 (137) F92     Cataract 9.4 (71)
10.1.2    H1 non-sedative antihistamines 17.7 (134) P74     Anxiety disorder/anxiety state 9.4 (71)
2.12       Narcotic analgesics 15.3 (116) L87     Bursitis/tendinitis/synovitis NOS 8.6 (65)
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In line with previous reports [11, 25, 26], we 
found a significant association between increased 
age and prevalence of polypharmacy. This could 
be due to the increase in the prevalence of age-re-
lated chronic diseases, which are accompanied 
by an increase in medications and possibly also 
because of prescribing for social problems [27]. 
However, in our new definition (≥ median number 
of drugs taken) there was not a significant asso-
ciation between increased age and prevalence of 
polypharmacy. This could be due to the increase 
of the threshold of polypharmacy that can pre-
vent labelling older adults with polypharmacy 
just because of the increase of comorbidities and 
drugs that may be necessary for them, commonly 
referred to as appropriate polypharmacy, as sug-
gested by Steinman et al. [3].
There was no difference in risk of polypharmacy 
between genders with the common definition of 
polypharmacy. Our findings were in line with those 
of other studies [11, 28]. However, there are stud-
ies that found an increased risk of polypharmacy 
in men [26] and women [14, 25]. A  higher prev-
alence of polypharmacy was also present in our 
study when we considered polypharmacy as a val-
ue equal to or greater than the median number of 
drugs (≥ 8) taken by the population. One explana-
tion can be that women tend to live longer than 
men, hence having more chronic health problems 
and needing more drugs. However, more studies 
are needed to assess whether there is a difference 
in risk of polypharmacy between genders.
As expected, the number of chronic health 
problems affects the number of medications tak-
en by the patient and this association has been 
well described in the literature [11, 14, 25, 28]. 
However, in our study there were some chronic 
health problems with a  stronger impact on the 
risk of polypharmacy, for example group classifi-
cation D (digestive problems) for polypharmacy as 
≥ 5 drugs and K (cardiovascular) for our definition 
(≥ the median number of drugs taken).
A  higher number of prescribers per patient 
was associated with higher risk of polypharmacy, 
namely for the common definition (≥ 5). One ex-
planation is that having multiple prescribers may 
unknowingly duplicate or induce contraindicated 
medication regimens due to lack of information 
available, which increases the risk of serious ad-
verse drug events [29]. On the other hand, more 
complex patients (with multimorbidity) need to be 
assisted by more doctors and take more drugs. To 
our knowledge, this is one of the first studies to 
assess the impact of having multiple prescribers 
on polypharmacy.
In agreement with previous reports [14, 26], car-
diovascular, metabolic and musculoskeletal medi-
cations were the most common in our study sam-
ple. This is in line with the most common chronic 
health problems described in Portugal [19], which 
are cardiovascular (such as lipid disorder and hy-
pertension), metabolic (such as diabetes and obe-
sity) and musculoskeletal (such as back pain syn-
drome, osteoarthritis and osteoarthrosis) problems 
[30]. This highlights the importance of prescribing 
the best drug option for the patient. 
Our proposed definition had better specific-
ity in detecting PIM than the common defini-
tion, which means a much lower number of false 
positive “results”. This occurred at the cost of 
diminished sensitivity. However, we found a sim-
ilar mean number of PIMs in both groups (with 
polypharmacy and without) according to both 
definitions. These results are in line with those of 
Steinman et al. [3], which raises the question of 
whether we should raise the threshold to avoid 
the risk of under-use as there does not seem to 
be a greater risk of inappropriate prescription. The 
advantage of our definition compared to others 
that propose a  higher threshold is that it is not 
a rigid definition and can be adapted to a specific 
population morbidity burden, since different pop-
ulations have different needs. Therefore, it would 
be like standardizing the risk of inappropriate pre-
scription according to the population’s morbidity 
burden to help us compare the impact of different 
health systems and policies on this problem.
There are some limitations in this study.
Firstly, we used a  12-month period to assess 
the chronic prescribed medication, which can in-
crease the prevalence of polypharmacy, since med-
ication could have been ceased or not purchased 
(non-compliance). Therefore, the number of medi-
cations per older adult may be overestimated.
Secondly, since the SPMS could not provide us 
with data from both autonomous regions (Madei-
ra and Azores), representing 1.7% of the sample, 
data were collected by local GPs, making the sam-
ple and data processes in these two regions dif-
ferent from the rest. Nevertheless, randomisation 
was performed for these data.
Thirdly, we intended to evaluate the effects of 
level of education on polypharmacy. This was not 
possible due to lack of information in the patients’ 
electronic records. 
Fourthly, the sample size was chosen to achieve 
a  sufficiently precise overall proportion estimate 
of polypharmacy in the Portuguese older adults’ 
population, but not to find differences among dif-
ferent population strata.
Fifthly, we could not find any study using an 
approach like ours (polypharmacy as ≥ median 
number of drugs taken by the population) and 
had great difficulty making comparisons between 
different studies. 
Sixthly, we could not have data on over-the-
counter medications, so the prevalence of poly-
pharmacy may be underestimated. 
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Finally, this was a  cross-sectional study and 
so no causal relationship could be proven, and 
we could not study the health consequences of 
polypharmacy, namely drug-drug interactions 
and adverse drug reactions. Therefore, longitu-
dinal studies are needed to understand whether 
these factors are responsible for the prevalence 
of polypharmacy. However, we intended to study 
prevalence and raise questions and not determine 
causality, so other studies are required to study 
causality, frequency and outcomes.
In conclusion, this study found a  high preva-
lence of polypharmacy in the studied sample; the 
most important factors were number of chronic 
health problems and number of prescribers in both 
used definitions and age in the most common 
definition and being female in our new definition. 
Polypharmacy should consider medical con-
straints, pathological needs and patients’ feelings 
and fears, implying future studies on the accurate-
ness of prescription and the need of deprescrip-
tion.
We think that our new definition of polyphar-
macy is of relevance for practitioners since it will 
identify patients with higher risks. However, fur-
ther studies are needed to increase its reliability 
and usefulness.
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